Compound Detail
CHEMBL4298037
RETIFANLIMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4298037 |
| Name | RETIFANLIMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
10
Known Names
20
Indications
1
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Programmed cell death protein 1 antagonist | ANTAGONIST | Programmed cell death protein 1 | ✓ | ✓ |
Indications
Carcinoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma, Squamous Cell Neoplasms Neoplasms Carcinoma, Non-Small-Cell Lung Breast Neoplasms Breast Neoplasms Breast Neoplasms Endometrial Neoplasms Esophageal Neoplasms Glioblastoma Head and Neck Neoplasms Liposarcoma Malignant Carcinoid Syndrome Neuroendocrine Tumors Pancreatic Neoplasms Paraganglioma Sarcoma Sarcoma
ATC Classification
L01FF10
retifanlimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Data from ChEMBL 36 via Core Engine